312314-26-4

Basic information

• Product Name: 1H-Indole, 6-fluoro-4-(phenylMethoxy)-
• Synonyms: 1H-Indole, 6-fluoro-4-(phenylMethoxy)-;4-Benzyloxy-6-Fluoro 1H-indole
• CAS NO: 312314-26-4
• Molecular Formula: C₁₅H₁₂FNO
• Molecular Weight: 241.2602832
• Mol File: 312314-26-4.mol
• Article Data: 1

Chemical Properties

• Melting Point: 83-84 °C
• Boiling Point: 401.5±30.0 °C(Predicted)
• Appearance: /
• Density: 1.264±0.06 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 16.57±0.30(Predicted)
• CAS DataBase Reference: 1H-Indole, 6-fluoro-4-(phenylMethoxy)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Indole, 6-fluoro-4-(phenylMethoxy)-(312314-26-4)
• EPA Substance Registry System: 1H-Indole, 6-fluoro-4-(phenylMethoxy)-(312314-26-4)

Safety Data

• Hazardous Substances Data: 312314-26-4(Hazardous Substances Data)

Usage

General Description

1H-Indole, 6-fluoro-4-(phenylmethoxy)- is a synthetic compound with the molecular formula C17H13FNO. It is a derivative of indole, containing a fluorine atom at the 6th position and a phenylmethoxy group at the 4th position of the indole ring. 1H-Indole, 6-fluoro-4-(phenylmethoxy)- has potential applications in the field of medicinal chemistry and drug development, as indole derivatives have been studied for their diverse biological activities, including anti-inflammatory, antimicrobial, and anticancer properties. The specific substitution pattern in 1H-Indole, 6-fluoro-4-(phenylmethoxy)- may also confer unique pharmacological properties, making it a molecule of interest for further research and exploration.

Upstream product

• 312314-24-2 4-benzyloxy-6-fluoroindole-2-carboxylic acid 
• 372-20-3 3-fluorophenol 
• 348-28-7 4-fluoro-2-hydroxybenzaldehyde 
• 202857-89-4 2-(benzyloxy)-4-fluorobenzaldehyde 
• 312314-22-0 methyl 4-benzyloxy-6-fluoroindole-2-carboxylate 

Downstream Products

• 312314-28-6 (4-benzyloxy-6-fluoro-1H-indol-3-yl)-oxo-acetyl chloride 
• 312314-32-2 4-benzyloxy-6-fluoro-N,N-dimethyltryptamine 
• 312314-30-0 N,N-diethyl-4-benzyloxy-6-fluoroindol-3-ylglyoxalylamide 
• 1265218-77-6 methyl 2-(4-(benzyloxy)-6-fluoro-1H-indol-3-yl)-2-oxoacetate 
• 1265218-78-7 2-(4-(benzyloxy)-6-fluoro-1H-indol-3-yl)ethanol 
• 1265218-79-8 2-(4-(benzyloxy)-1-ethyl-6-fluoro-1H-indol-3-yl)ethanol 
• 1265219-32-6 C₂₃H₃₀FNO₂Si 
• 1265219-33-7 C₂₅H₃₄FNO₂Si 
• 1265219-34-8 C₂₀H₂₂FNO₄S 

Relevant articles and documents

Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines

A series of fluorinated analogues of the hallucinogenic tryptamines N,N-diethyltryptamine (DET), 4-hydroxy-N,N-dimethyltryptamine (4-OH-DMT, psilocin), and 5-methoxy-DMT was synthesized to investigate possible explanations for the inactivity of 6-fluoro-DET as a hallucinogen and to determine the effects of fluorination on the molecular recognition and activation of these compounds at serotonin receptor subtypes. The target compounds were evaluated using in vivo behavioral assays for hallucinogen-like and 5-HT(1A) agonist activity and in vitro radioligand competition assays for their affinity at 5-HT(2A), 5-HT(2C), and 5-HT(1A) receptor sites. Functional activity at the 5-HT(2A) receptor was determined for all compounds. In addition, for some compounds functional activity was determined at the 5-HT(1A) receptor. Hallucinogen-like activity, evaluated in the two-lever drug discrimination paradigm using LSD-trained rats, was attenuated or abolished for all of the fluorinated analogues. One of the tryptamines, 4-fluoro-5-methoxy-DMT (6), displayed high 5-HT(1A) agonist activity, with potency greater than that of the 5-HT(1A) agonist 8-OH-DPAT. The ED50 of 6 in the two-lever drug discrimination paradigm using rats trained to discriminate the 5-HT(1A) agonist LY293284 was 0.17μmol/kg, and the K(i) at [3H]8-OH-DPAT-labeled 5-HT(1A) receptors was 0.23 nM. The results indicate that fluorination of hallucinogenic tryptamines generally has little effect on 5-HT(2A/2C) receptor affinity or intrinsic activity. Affinity at the 5-HT(1A) receptor was reduced, however, in all but one example, and all of the compounds tested were full agonists but with reduced functional potency at this serotonin receptor subtype. The one notable exception was 4-fluoro-5-methoxy-DMT (6), which had markedly enhanced 5-HT(1A) receptor affinity and functional potency. Although it is generally considered that hallucinogenic activity results from 5-HT(2A) receptor activation, the present results suggest a possible role for involvement of the 5-HT(1A) receptor with tryptamines.